Table 1 Baseline characteristics of study population.
Training and cross-validation | Testing | p | |
|---|---|---|---|
N = 1540 | N = 388 | ||
Age | 69.12 ± 12.43 | 68.45 ± 12.65 | 0.343 |
Male, n (%) | 1117 (72.53) | 295 (76.03) | 0.164 |
BMI, Kg/m2 | 25.70 ± 4.07 | 25.93 ± 3.31 | 0.254 |
Hypertension, n (%) | 1022 (66.36) | 248 (63.92) | 0.364 |
Diabetes, n (%) | 558 (36.23) | 150 (38.66) | 0.376 |
Systolic BP, mmHg | 131.84 ± 20.29 | 132.08 ± 20.34 | 0.838 |
Diastolic BP, mmHg | 74.04 ± 11.49 | 73.97 ± 12.52 | 0.926 |
LVEF, % | 54.24 ± 12.03 | 53.84 ± 10.65 | 0.721 |
Glucose, mg/dL | 121.28 ± 41.65 | 122.83 ± 41.92 | 0.569 |
Cholesterol, mg/dL | 173.83 ± 42.01 | 174.16 ± 40.29 | 0.892 |
LDL-C, mg/dL | 106.73 ± 34.63 | 108.11 ± 33.71 | 0.488 |
HDL-C, mg/dL | 43.32 ± 12.36 | 43.13 ± 11.02 | 0.770 |
Triglyceride, mg/dL | 136.74 ± 83.24 | 137.03 ± 88.30 | 0.953 |
TC/HDL-C ratio | 4.28 ± 1.52 | 4.26 ± 1.43 | 0.809 |
Creatinine | 1.54 ± 1.68 | 1.52 ± 1.72 | 0.890 |
CAD severity | |||
SVD, n (%) | 106 (27.32) | 438 (28.44) | 0.701 |
DVD, n (%) | 126 (32.47) | 507 (32.92) | |
TVD, n (%) | 155 (39.95) | 594 (38.57) | |
Total stents, n | 1.85 ± 1.08 | 1.78 ± 1.01 | 0.295 |
Total stents size, mm | 3.06 ± 0.44 | 3.05 ± 0.40 | 0.670 |
Total stents length, mm | 23.36 ± 5.99 | 23.10 ± 6.27 | 0.494 |
Medication | |||
ACE inhibitor/ARB, n (%) | 842 (54.68) | 210 (54.12) | 0.845 |
β-blocker, n(%) | 787 (51.10) | 199 (51.29) | 0.948 |
Calcium channel blocker, n (%) | 586 (38.05) | 163 (42.01) | 0.153 |
Diuretics, n (%) | 194 (12.60) | 54 (13.92) | 0.488 |
Statin, n (%) | 897 (58.25) | 219 (56.44) | 0.520 |
